Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Regeneron Pharmaceuticals stock on November 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Regeneron Pharmaceuticals Trading Up 2.6%

NASDAQ:REGN opened at $767.96 on Friday. The business’s 50-day moving average is $682.40 and its two-hundred day moving average is $599.63. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $790.98. The firm has a market capitalization of $80.71 billion, a PE ratio of 18.39, a price-to-earnings-growth ratio of 2.15 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same quarter in the prior year, the business earned $12.46 earnings per share. The company’s revenue was up .9% compared to the same quarter last year. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on REGN shares. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a research report on Friday, December 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Wells Fargo & Company lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “equal weight” rating in a research note on Wednesday, December 10th. Scotiabank upped their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a research report on Monday, November 24th. Finally, Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $779.45.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Activest Wealth Management raised its stake in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares in the last quarter. Saudi Central Bank bought a new position in Regeneron Pharmaceuticals during the first quarter worth $27,000. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the third quarter worth $27,000. Colonial Trust Advisors acquired a new position in Regeneron Pharmaceuticals in the first quarter worth $32,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at $31,000. Institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 7.02% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.